XML 42 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration and License Agreement - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 15 Months Ended 24 Months Ended 43 Months Ended
Aug. 31, 2014
Jan. 31, 2017
Dec. 31, 2016
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Mar. 31, 2018
Dec. 31, 2018
Mar. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Collaboration and license revenue       $ 5,331 $ 2,410          
Deferred revenue     $ 45,000 28,227 42,590 $ 45,000 $ 33,558 $ 28,227   $ 28,227
Short-term receivable from collaboration partner     45,000     45,000 1,013      
Collaborative Agreement | Sanofi (Aventis Inc.)                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront cash received under collaboration agreement $ 35,000                  
Up-front equity investment 10,000                  
Additional equity investments received                   14,000
Eligible to receive one-time, non-refundable contingent payment 25,000                  
Project non-refundable continuation payment 45,000                  
Milestone payment received 25,000         $ 25,000        
Continuation payment, amount received   $ 45,000 $ 45,000              
Upfront cash payment 34,300                  
Net fair value allocated to equity 700                  
Variable consideration 25,000                  
Collaboration and license revenue       5,300 2,400          
Deferred revenue       28,200       28,200   28,200
Deferred revenue recognized               16,800    
Short-term receivable from collaboration partner       0     1,013 $ 0   $ 0
Prepayment from collaboration partner       6,090     $ 4,400      
Reduction in research and development expenses due to RPP reimbursements       $ 2,800 $ 0          
Collaborative Agreement | Sanofi (Aventis Inc.) | Forecast                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Fixed fee                 $ 45,000  
Transaction price for extended term                 $ 45,000  
Collaborative Agreement | Maximum | Sanofi (Aventis Inc.)                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Funding from approved in-kind research and clinical activities 45,000                  
Additional research and development funding for collaboration $ 15,000